SCHEMBL13197282

SCHEMBL13197282

O=C1OC(=O)[C@H]2[C@@H]1[C@H]1C=C[C@H]2C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ GMNN O75496 1/20 0.42
▸ PPM1B O75688 1/20 0.42
▸ PPP1CC P36873 1/20 0.42
▸ TFPI2 P48307 1/20 0.42
▸ PPP5C P53041 1/20 0.42
▸ PPP1CA P62136 1/20 0.42
▸ PMP22 Q01453 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ THPO P40225 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ HTT P42858 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL533614 1.00 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2RAB9ALMNA
SCHEMBL27496 1.00 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2RAB9ALMNA
SCHEMBL3130301 1.00 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2RAB9ALMNA
SCHEMBL13216620 1.00 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2RAB9ALMNA
SCHEMBL196877 1.00 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2RAB9ALMNA
SCHEMBL12268145 1.00 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2RAB9ALMNA
SCHEMBL16704819 1.00 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2RAB9ALMNA
SCHEMBL13397502 1.00 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2RAB9ALMNA
SCHEMBL9579531 1.00 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2RAB9ALMNA
SCHEMBL12549702 1.00 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3057966-B1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE PROCOS SPA (IT) 2017-07-26 — — EP claimed
US-9518047-B2 Process for the industrial synthesis of lurasidone PROCOS S.P.A. (IT) 2016-12-13 — — US claimed
EP-3057966-A1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE Procos S.p.A. (IT) 2016-08-24 — — EP claimed
US-20160237077-A1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE PROCOS S.P.A. (IT) 2016-08-18 — — US claimed
WO-2015056205-A1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE PROCOS S.P.A. (IT) 2015-04-23 — — WO claimed
EP-3057966-B1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE PROCOS SPA (IT) 2017-07-26 — — EP disclosed
EP-3057966-B1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE PROCOS SPA (IT) 2017-07-26 — — EP disclosed
US-9518047-B2 Process for the industrial synthesis of lurasidone PROCOS S.P.A. (IT) 2016-12-13 — — US disclosed
US-9518047-B2 Process for the industrial synthesis of lurasidone PROCOS S.P.A. (IT) 2016-12-13 — — US disclosed
US-9518047-B2 Process for the industrial synthesis of lurasidone PROCOS S.P.A. (IT) 2016-12-13 — — US disclosed
US-9518047-B2 Process for the industrial synthesis of lurasidone PROCOS S.P.A. (IT) 2016-12-13 — — US disclosed
EP-3057966-A1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE Procos S.p.A. (IT) 2016-08-24 — — EP disclosed
US-20160237077-A1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE PROCOS S.P.A. (IT) 2016-08-18 — — US disclosed
US-20160237077-A1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE PROCOS S.P.A. (IT) 2016-08-18 — — US disclosed
US-20160237077-A1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE PROCOS S.P.A. (IT) 2016-08-18 — — US disclosed
US-20160237077-A1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE PROCOS S.P.A. (IT) 2016-08-18 — — US disclosed
WO-2015056205-A1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE PROCOS S.P.A. (IT) 2015-04-23 — — WO disclosed
WO-2015056205-A1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE PROCOS S.P.A. (IT) 2015-04-23 — — WO disclosed
US-20100210803-A1 NORBORNENE-BASED POLYMER HAVING LOW DIELECTRIC CONSTANT AND LOW-LOSS PROPERTIES AND INSULATING MATERIAL USING THE SAME SAMSUNG ELECTRO-MECHANICS CO., LTD. 2010-08-19 — — US disclosed
US-20100210803-A1 NORBORNENE-BASED POLYMER HAVING LOW DIELECTRIC CONSTANT AND LOW-LOSS PROPERTIES AND INSULATING MATERIAL USING THE SAME SAMSUNG ELECTRO-MECHANICS CO., LTD. 2010-08-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237077-A1 PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE REN, DCXR, ADRA1D ALDH1A1 176/4885TDP1 4433/4885SMN1; SMN2 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback